Business Context and Reporting Period
Company: Pavmed Inc. (PAVM)
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2024
Reporting Period: Event date March 13, 2024; Signed March 14, 2024
Context: The filing reports a material definitive agreement and modification to security holder rights involving Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed Inc.
Key Financial Metrics
This filing does not contain consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for Pavmed Inc. The financial data provided relates specifically to a capital transaction at the subsidiary level:
- Transaction Type: Series B Offering and Exchange of Preferred Stock by Lucid Diagnostics Inc.
- New Capital Raised: Sale of 12,495 shares of Series B Convertible Preferred Stock at $1,000 per share (Total: $12,495,000).
- Exchange Activity: Investors exchanged 13,625 shares of Series A Preferred Stock and 10,670 shares of Series A-1 Preferred Stock for 31,790 shares of Series B Preferred Stock.
- Additional Exchange: Included in the above is an immediate exchange of 5,670 shares of Series A-1 Preferred Stock (previously sold at $1,000/share) for Series B Preferred Stock.
Material Changes Versus Prior Period
The filing details a structural change in the capitalization of the subsidiary, Lucid Diagnostics Inc., rather than a period-over-period operational comparison:
- Capital Structure: Designation of new Series B Convertible Preferred Stock and amendment of Series A-1 Preferred Stock designations.
- Ownership Rights: Material modification to the rights of security holders regarding the exchange of Series A and Series A-1 stock for Series B stock.
- Registration Rights: Execution of a Registration Rights Agreement requiring the Company to file a registration statement for the resale of Common Stock issuable upon conversion of the Series B Preferred Stock.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the closing of the transaction on March 13, 2024, and the filing of necessary certificates with the Delaware Secretary of State. Detailed descriptions of the offering are incorporated by reference from a separate 8-K filed by Lucid Diagnostics on March 14, 2024.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard implications of a capital raise and security exchange. The primary contingency noted is the requirement to file a future registration statement for the resale of underlying common stock.
Unusual Items: The transaction involves a complex exchange of multiple classes of preferred stock (Series A and A-1) into a new class (Series B) alongside a new cash investment.
Investor Verification Checklist
- Verify the full terms of the Series B Preferred Stock in the "Preferred Offering 8-K" filed by Lucid Diagnostics on March 14, 2024, as referenced in this document.
- Confirm the dilution impact on existing Pavmed Inc. shareholders resulting from the conversion features of the new Series B Preferred Stock.
- Review the Registration Rights Agreement (Exhibit 10.2) to understand the timeline and obligations for registering the resale of common stock.
- Assess the financial health and valuation of Lucid Diagnostics Inc. based on the $1,000 per share price established in this transaction.